Tap, William D.

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 4,071

Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials

D'Angelo, S. P., Mahoney, M. R., Van Tine, B. A., Atkins, J., Milhem, M. M., Jahagirdar, B. N., Antonescu, C. R., Horvath, E., Tap, W. D., Schwartz, G. K., et al. (2018) · The Lancet Oncology

Sarcoma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 759

Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor

Tap, W. D., Wainberg, Z. A., Anthony, S. P., Ibrahim, P. N., Zhang, C., Healey, J. H., Chmielowski, B., Staddon, A. P., Cohn, A. L., Shapiro, G. I., et al. (2015) · New England Journal of Medicine

Musculoskeletal synovial abnormalities and treatmentsRheumatoid Arthritis Research and Therapies

Cited by 582

Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4 -Amplified Well-Differentiated or Dedifferentiated Liposarcoma

Dickson, M. A., Tap, W. D., Keohan, M. L., D'Angelo, S. P., Gounder, M. M., Antonescu, C. R., Landa, J., Qin, L.-X., Rathbone, D. D., Condy, M. M., et al. (2013) · Journal of Clinical Oncology

Sarcoma Diagnosis and TreatmentAdvanced Breast Cancer Therapies

Cited by 399

CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought

Klein, M. E., Kovatcheva, M., Davis, L. E., Tap, W. D., & Koff, A. (2018) · Cancer Cell

Advanced Breast Cancer TherapiesPI3K/AKT/mTOR signaling in cancer

Cited by 378

Cancer Disparities and Health Equity: A Policy Statement From the American Society of Clinical Oncology

Patel, M. I., Lopez, A. M., Blackstock, W., Reeder-Hayes, K., Moushey, E. A., Phillips, J., & Tap, W. (2020) · Journal of Clinical Oncology

Global Cancer Incidence and ScreeningHealth disparities and outcomes

Cited by 338

Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets

Nacev, B. A., Sanchez-Vega, F., Smith, S. A., Antonescu, C. R., Rosenbaum, E., Shi, H., Tang, C., Socci, N. D., Rana, S., Gularte-Mérida, R., et al. (2022) · Nature Communications

Sarcoma Diagnosis and TreatmentChromatin Remodeling and Cancer

Cited by 232

Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma

Khanna, C., Fan, T. M., Gorlick, R., Helman, L. J., Kleinerman, E. S., Adamson, P. C., Houghton, P. J., Tap, W. D., Welch, D. R., Steeg, P. S., et al. (2014) · Clinical Cancer Research

Sarcoma Diagnosis and TreatmentCancer Cells and Metastasis

Cited by 178

Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma

Tap, W. D., Villalobos, V. M., Cote, G. M., Burris, H., Janku, F., Mir, O., Beeram, M., Wagner, A. J., Jiang, L., Wu, B., et al. (2020) · Journal of Clinical Oncology

Bone Tumor Diagnosis and TreatmentsSarcoma Diagnosis and Treatment

Cited by 165

MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition

Kovatcheva, M., Liu, D. D., Dickson, M. A., Klein, M. E., O’Connor, R., Wilder, F. O., Socci, N. D., Tap, W. D., Schwartz, G. K., Singer, S., et al. (2015) · Oncotarget

Cancer-related Molecular PathwaysTelomeres, Telomerase, and Senescence

Cited by 142

ATRX is a regulator of therapy induced senescence in human cells

Kovatcheva, M., Liao, W., Klein, M. E., Robine, N., Geiger, H., Crago, A. M., Dickson, M. A., Tap, W. D., Singer, S., & Koff, A. (2017) · Nature Communications

Telomeres, Telomerase, and SenescenceGenomics and Chromatin Dynamics

Cited by 89

Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma

D’Angelo, S. P., Richards, A. L., Conley, A. P., Woo, H. J., Dickson, M. A., Gounder, M., Kelly, C., Keohan, M. L., Movva, S., Thornton, K., et al. (2022) · Nature Communications

Cancer Immunotherapy and BiomarkersSarcoma Diagnosis and Treatment

Cited by 60

A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses

Seligson, N. D., Chen, J. L., Goodrich, A. C., Van Tine, B. A., Campbell, J. D., Richards, A. L., Antonescu, C. R., Liebner, D. A., Milhem, M. M., Streicher, H., et al. (2024) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersSarcoma Diagnosis and Treatment

Cited by 21